n severe heart failure, there is marked upregulation of stanniocalcin 1 (STC1) protein in cardiomyocytes. 1 STC1 is a glycoprotein hormone that is expressed in many organs and is believed to contribute to calcium homeostasis in the gut, heart, brain, and other organs. The fact that, although STC1 is widely distributed in tissues, circulating STC1 is undetectable, except in pregnancy, 2 is strongly suggestive of its autocrine or paracrine role.
In fetal mouse cardiac muscles, STC1 appears in the 8.5-to 15.5-day-old embryo and presumably plays a role in myogenic differentiation. 3 Cardiac tissue in patients with heart failure shows markedly increased STC1 protein expression and using immunohistochemistry, diffused staining of STC1 in cardiomyocytes, particularly predominant in the nucleus, is apparent. Further, in cultured adult rat cardiomyocytes, which are used as a model of heart failure, the STC1 protein inhibits Ca 2+ influx via the L-type Ca 2+ channel and decreases intracellular calcium ([Ca 2+ ]i). 1 However, the localization of the STC1 receptor in the cardiomyocyte is still unclear.
STC1 is believed to contribute to calcium homeostasis in a variety of tissues. In the normal gut STC1 decreases the absorption of calcium and stimulates the absorption of phosphate, 4 in the brain it protects the neurons against harmful calcium levels that occur after hypoxia/ischemic damage 5 and in macrophages it blunts the increase in [Ca 2+ ]i and attenuates chemokinesis and modulates the immune/inflammatory response. 6 However, the role of STC1 in the heart is still unclear, so in the present study we examined the physiological effects of STC1 on cell shortening and the Ca 2+ transients in fresh isolated adult rat cardiomyocytes and, moreover, the effects of STC1 on ouabaininduced cell hypercontracture and cytosolic Ca 2+ overload.
heparin (400 U/kg, ip), the heart was rapidly excised and perfused retrogradely via the aorta using the Langendorff method. The heart was first perfused with Ca 2+ free solution (solution-A) containing (in mmol/L): NaCl 137, KCl 5.4, MgCl2 1, HEPES 5, dextrose 22, taurine 20, creatine 5, sodium pyruvate 5, adjusted to pH 7.4 with NaOH (37°C). After 5 min of initial perfusion, the heart was perfused for approximately 30 min with solution-A plus 0.1 mmol/L CaCl2 with 0.5 mg/ml collagenase. The enzyme was then washed out by perfusing with solution-A plus 0.1 mmol/L CaCl2 for 5 min. The left ventricle was removed from the heart, chopped into small pieces, and then shaken at 37°C for 10 min in a glass conical flask containing 30 ml of solution-A plus 0.1 mmol/L CaCl2. The cell suspension was filtered (200 m mesh), sedimented in a 50-ml glass beaker for 5 min, and the supernatant then replaced with a higher Ca 2+ -containing solution; the Ca 2+ was increased in 3 steps up to 1 mmol/L. Once isolated, the cells were resuspended in a culture medium composed of 5% fetal calf serum, 47.5% M199 and 47.5% F-12 at room temperature until use.
Measurement of Cell Shortening
The chamber with the cardiomyocytes was placed on the stage of an inverted phase contrast microscope (Zeiss, Axio skop), and the cardiomyocytes were perfused for 30 min at a flow rate of 2 ml/min with a control solution containing (in mmol/L) NaCl, 137; KCl, 5.4; MgCl2, 1; CaCl2, 1.8; HEPES, 5; and dextrose, 5.5 or control solution plus r-hSTC1 (0.25, 2.5, or 25 nmol/L) with or without 1 mmol/L ouabain. The cells were electrically stimulated at a frequency of 0.5 Hz using a pair of extracellular platinum electrodes and magnified using ×5 objective lens. The magnified image of the contracting and relaxing myocytes was transmitted by CCD camera (Fast Scan 250 frames/s) to a television monitor. Changes in cell length were measured prior to the treatment and after perfusion for 10, 20, and 30 min by Scan Image software. The signal from the monitor detector was calibrated to indicate changes in the cell length in micrometers. The fraction of shortening is expressed as the amplitude of cell shortening/resting cell length and the percentage of baseline fraction of cell shortening is shown.
Measurement of Ca 2+ Transient
The Ca 2+ fluoroprobe fluo-3 AM was used to measure the Ca 2+ transient. Fresh isolated adult rat cardiomyocytes were loaded with 10 mol/L fluo-3 at 37°C in the dark for 30 min and attached to a laminin-coated glass cover slip of a thermostatically controlled chamber. The chamber was placed on the stage of an inverted phase contrast microscope (Zeiss, Axiovert S100TV) with a ×40 objective lens.
Fluo-3-loaded myocytes were electrically stimulated at a frequency of 0.5 Hz using a pair of extracellular platinum electrodes and excited with light at 485 nm wavelength. Fluorescence (530 nm) was detected using a photomultiplier tube and was analyzed using Mac Lab/8s software. The [Ca 2+ ]i level was evaluated by the intensity of fluorescence at 530 nm, which increases with an increase in [Ca 2+ ]i level; this was expressed as the percentage of the amplitude of Ca 2+ transient prior to treatment.
Counting Cell Hypercontracture
Isolated adult rat cardiomyocytes with 1 mmol/L ouabain with (0.25, 0.5, 0.75, 1.0, 1.25, 2.5, or 12.5 nmol/L of rhSTC1) or without r-hSTC1 were put into the wells of a microplate, which was placed on the stage of an inverted phase contrast microscope (Nikon) enclosed in a box at a controlled temperature (37-38°C). After a 60-min exposure, cell hypercontracture was defined as 50% shortening of the initial length, expressed as the percentage of the total viable cells prior to treatment.
Data Analysis
Data are presented as mean ± SEM, and the number of experiments is shown as n. Intergroup comparisons were performed using Student's t-test for 2 groups or by ANOVA followed by Tukey's test for multiple groups. A value of p<0.05 was regarded as significant.
Results

Effects of STC1 on Fresh Isolated Adult Rat Cardiomyocytes
Cell shortening and the Ca 2+ transients were measured after exposure of the cells to 0.25, 2.5, or 25 nmol/L STC1.
The effect of STC1 on cell shortening is shown in Fig 2C) .
STC1 had no effect on cell shortening or the Ca 2+ transients in isolated fresh adult rat cardiomyocytes.
Effects of STC1 on Ouabain-Induced Cell Hypercontracture
When cardiomyocytes are exposed to toxic concentrations of ouabain (eg, >200 mol/L), many cells become overloaded with cytosolic Ca 2+ and undergo arrhythmic contraction and eventually contracture. 10 However, it has been recently reported that STC1 decreases the intracellular Ca 2+ concentration. 1, 5, 6 To evaluate the effects of STC1 on impaired cardiomyocytes, we examined whether it inhib- 
Effects of STC1 on Ca 2+ Transient and Cell Shortening During Ouabain Administration
Because STC1 inhibited ouabain-induced cell hypercontracture, we examined whether STC1 affected the Ca 2+ transients and cell shortening during ouabain administration.
Typical tracings of the Ca 2+ transients during ouabain administration with or without STC1 are shown in Fig 4A . 
Effects of STC1 on Ca 2+ Overload Induced by High-Frequency Electrical Stimulation
In order to verify by an alternative method that STC1 inhibited the diastolic [Ca 2+ ]i overload, the Ca 2+ transients were measured by stimulating the cardiomyocytes with high-frequency electrical stimulation. Cardiomyocytes were treated with 2.5 nmol/L STC1 for 20 min and electrically stimulated at a frequency of 6 Hz. 
Discussion
Although STC1 has been reported to decrease [Ca 2+ ]i in a variety of tissues, 1, 5, 6 the present study has revealed that it did not affect cell shortening or the Ca 2+ transients in fresh isolated cardiomyocytes. In cardiomyocytes exposed to ouabain, STC1 did not affect the amplitude of the Ca 2+ transients nor the fraction of cell shortening. On the other hand, STC1 prevented an increase in the diastolic [Ca 2+ ]i level induced by both ouabain and high-frequency electrical stimulation.
It is reported that the removal of Ca 2+ from cytosol is performed by the following transport systems: sarco (endo) plasmic reticulum Ca 2+ ATPase pump (SERCA) (70-80% of Ca 2+ removal in higher mammalian species and human myocardium), sarcolemmal Na + -Ca 2+ exchanger (20-30%), sarcolemmal Ca 2+ -ATPase (approximately 1%) and mitochondrial Ca 2+ uniporter (approximately 1%). 11 Among these transport systems, the SERCA and sarcolemmal Na + -Ca 2+ exchangers mainly contribute to the removal of Ca 2+ from cytosol during relaxation. Therefore, we speculate that STC1 might affect any of the Ca 2+ transporters and thus could play a role in calcium homeostasis under pathophysiological conditions.
Ouabain augments the intracellular sodium concentration ([Na + ]i) as a result of its inhibition of the Na + -K + ATPase. The increased [Na + ]i then leads to an increase in [Ca 2+ ]i via the Na + -Ca 2+ exchanger and induces the release of a large amount of Ca 2+ from the sarcoplasmic reticulum. [12] [13] [14] Therefore, the effect of STC1 may not be related to the Na + -K + ATPase, Ca 2+ influx via the Na + -Ca 2+ exchanger, and the release of Ca 2+ from ryanodine receptor, which is the cascade of the ouabain effect, and thus may not affect the positive inotropic effects induced by ouabain. Heart failure is a complex disorder, and many factors (Ca 2+ overload, oxidative stress, apoptosis etc) concurrently influence the development of contractile dysfunction. 15, 16 Three-morpholinosydnonimine (SIN-1) generates superoxide (O2 -) in addition to NO. The superoxide reacts with NO, generating a potent oxidizing product, peroxynitrite (ONOO -). 17 Therefore, we examined the effects of STC1 on the Ca 2+ transient during administration of SIN-1 under oxidative stress conditions, but STC1 did not prevent the decrease in the amplitude of the Ca 2+ transients induced by SIN-1 (data not shown). SIN-1 is associated with a reduction in the phosphorylation levels of phospholamban (PLB) and the peak amplitude of the Ca 2+ transient. 18, 19 However, STC1 might not affect the dysfunction of PLB induced by SIN-1.
STC1 prevented the cell hypercontracture that was induced by a high concentration of ouabain. When cardiomyocytes are exposed to a toxic concentration of ouabain (>200 mol/L), many cells are overloaded with cytosolic Ca 2+ and undergo arrhythmic contraction and eventually contracture, 10 so it is believed that cell hypercontracture is prevented by inhibiting the increase in the diastolic [Ca 2+ ]i level.
STC1 is also believed to act on the mitochondria. McCudden et al suggested that STC1 receptors exist in the inner mitochondrial matrix of the liver and kidney, and that in vitro STC1 stimulated electron transfer in the submitochondrial particles. 20 In addition, enlarged muscle mitochondria, increased oxygen consumption, and metabolic wasting have been observed in STC1 transgenic mice. 21 We have recently revealed that exposure of rat cardiomyocytes to 1 mmol/L ouabain results in mitochondrial Ca 2+ overload and cell hypercontracture. 22, 23 Moreover, Liu et al have shown the ouabain-altered interaction of a fraction of the Na + -K + ATPase, leading to the generation of reactive oxygen species from mitochondria, independent of that leading to the increase in [Ca 2+ ]i. 24 Therefore, STC1 may directly or indirectly act on the mitochondria and prevent ouabaininduced cell hypercontracture.
Conclusion
STC1 did not affect cell shortening or the Ca 2+ transients in fresh isolated rat cardiomyocytes, but did prevent the increase in the diastolic [Ca 2+ ]i level and ouabain-induced cell hypercontracture. Consequently, although STC1 has no physiological effect on the normal heart, it might protect cardiomyocytes from pathophysiological conditions such as the failing heart.
